Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IS-002 for intraoperative imaging in prostate cancer
NCT04574401Phase 1Completed
- Sponsor
- Intuitive Surgical
- Start
- Oct 2020
- Primary completion
- Sep 2021
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sonzivotide filricianine in prostate cancer (PCa), sponsored by Intuitive Surgical. Primary endpoint: Treatment-emergent adverse events at 14 days. Started Oct 2020; status: completed.
02
Drugs
sonzivotide filricianine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04574401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04574401.